Industry sponsorship and research outcome: systematic review with meta-analysis
Clinical research is widely sponsored by drug and device companies. We investigated whether industry sponsored drug and device studies have more favorable outcomes and differ in risk of bias, compared with studies having other sources of sponsorship. This review is an update of a previous Cochrane review.
In this update we searched MEDLINE and Embase (2010 to February 2015), Cochrane Methodology Register (2015, Issue 2) and Web of Science (June 2015). We included empirical studies that quantitatively compared primary research studies of drugs or medical devices sponsored by industry with studies with other sources of sponsorship. Two assessors included papers, extracted data and assessed risk of bias. Outcomes included favorable results, favorable conclusions, effect size, risk of bias and whether conclusions agreed with results.
We included 27 additional papers in this update (review now includes 75 papers). Industry sponsored studies more often had favorable efficacy results, RR: 1.27 (95% CI 1.17–1.37), no difference in harms results RR: 1.37 (95% CI 0.64–2.93) and more often favorable conclusions RR: 1.34 (95% CI 1.19–1.51) compared with non-industry sponsored studies. Nineteen papers reported on sponsorship and efficacy effect size, but could not be pooled due to differences in reporting of data and heterogeneity of results. Comparing industry and non-industry sponsored studies, we did not find a difference in risk of bias from sequence generation, allocation concealment, follow-up and selective outcome reporting. However, industry sponsored studies more often had low risk of bias from blinding, RR: 1.25 (95% CI 1.05–1.50), compared with non-industry sponsored studies.
Drug and device studies sponsored by manufacturing companies have more favorable efficacy results and conclusions than studies sponsored by other sources.
KeywordsIndustry sponsorship Conflicts of interest Clinical trials Outcomes Methodological quality Bias
We thank Jeremy Cullis (clinical librarian) at Macquarie University for developing the search strategy and running the database searches of this update. We thank the authors of the included papers for sharing their raw data. We thank Sergio Sismondo and Octavian A. Busuioc who co-authored the previous review. The authors were personally salaried by their institution during the period of the review. The study received no external funding.
Development of protocol (AL, BM, JL, JS and LB); study inclusion (BM, JL, JS and LB); data extraction (AL, BM, JL and JS); data analysis and interpretation of results (all authors); writing of manuscript (all authors).
Compliance with ethical standards
Conflicts of interest
All review authors are authors of the some of the previous reviews and included studies. In 2015–2018, Joel Lexchin was a paid consultant on three projects: one looking at indication-based prescribing (United States Agency for Healthcare Research and Quality), a second to develop principles for conservative diagnosis (Gordon and Betty Moore Foundation) and a third deciding what drugs should be provided free of charge by general practitioners (Government of Canada, Ontario Supporting Patient Oriented Research Support Unit and the St Michael’s Hospital Foundation). He also received payment for being on a panel that discussed a pharmacare plan for Canada (Canadian Institute, a for-profit organization). He is currently a member of research groups that are receiving money from the Canadian Institutes of Health Research and the Australian National Health and Medical Research Council. He is member of the Foundation Board of Health Action International and the Board of Canadian Doctors for Medicare. In 2015 and 2016, Barbara Mintzes was retained as an expert witness by the law firm representing the plaintiffs in an application for a Canadian class action on cardiovascular risks of testosterone supplements. She was a member of the Health Action International—Europe Association Board from 2012 to 2015. The review authors have no other relevant interests.
- 2.PhRMA. Pharmaceutical marketing in perspective: its value and role as one of many factors informing prescribing. http://phrma-docs.phrma.org/sites/default/files/pdf/phrma_marketing_brochure_influences_on_prescribing_final.pdf. Accessed 26 April 2018
- 7.Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig WD, Lieb K (2010) The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials. Dtsch Arztebl Int 107:279–285PubMedPubMedCentralGoogle Scholar
- 12.Higgins JPT, Green S (2011) cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane collaboration. http://www.cochrane-handbook.org. Accessed 26 April 2018
- 14.Lundh A, Lexchin J, Sismondo S, Busuioc OA, Bero L (2011) Industry sponsorship and research outcome. Cochrane Database Syst Rev 9:MR000033Google Scholar
- 18.The Cochrane Collaboration (2014) Review Manager (RevMan), version 5.3.5.: The Nordic Cochrane Centre, CopenhagenGoogle Scholar